Societal to Receive Greater Portion of Profit Sharing from Verapamil PM Product Sales Societal Awarded Potential New GMP Manufacturing Agreements for Multiple Additional Lannett Products SAN DIEGO...
MALVERN, Pa., April 16, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that Recro Gainesville LLC, its CDMO division, has amended its existing license and supply agreement with Teva Pharmaceutical to extend the agreement for six years, effective January 1, 2019.
Mylan Pharmaceuticals Receives FDA Warning Letter
In an investigation that spans 12 companies and 24 drugs, Evercore ISI’s Umer Raffat said he believes Teva could face a liability of $300 million to $700 million, while Mylan could face a $380 million to $770 million liability. Those numbers are strictly based on the drugs “most likely” to be involved in the probe of which Raffat and company “are aware.”
Rusan Pharma Ltd fails EDQM Inspection